Acadia’s Persistence With Pimavanserin In Parkinson’s Psychosis Pays Off
This article was originally published in Pharmaceutical Approvals Monthly
After meeting with FDA, Acadia announces it needs only one pivotal study for pimavanserin. The company has canceled a second study and expects to file at the end of 2014. Faster NDA pathway could mean launch a year earlier than expected.